{"title":"[根据tb -生物芯片测试系统数据,新发多药耐药结核分枝杆菌患者早期使用储备化疗方案的临床和x线变化]。","authors":"","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Clinical and X-ray changes were comparatively studied in new-onset tuberculosis patients excreting susceptible Mycobacterium tuberculosis (MBT) and mutidrug resistant (MDR) MBT. Eighty tuberculosis patients who had not received antituberculous drugs were followed up. Before chemotherapy, sputum was tested in all cases, by using the TB-biochip system, to determine drug susceptibility of MBT. According to the results of microchip diagnosis, the patients were divided into 2 groups: 1) patients with primary MRD MBT (a study group) and 2) those with MBT susceptible to all drugs (a control group). A chemotherapy regimen involving a combination of reserve drugs was given in Group 1 while Group 2 received standard regimen 1 that comprised basic series drugs. The timely use of the adequate therapy regimen in patients with MDR tuberculosis could achieve a high efficiency of therapy in a short period in terms of the bacterial excretion rate in 97.5 and 100% and in the terms of the decay cavity healing rate in 92.5 and 97.5% in Groups 1 and 2, respectively At the same time after termination of a 6-month course of therapy, both groups showed a preponderance of minimum residual changes as scars (37.5 and 45.0%) and fibrous foci (52.5 and 50.0%).</p>","PeriodicalId":37828,"journal":{"name":"Tuberculosis and Lung Diseases","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[CLINICAL AND X-RAY CHANGES IN PATIENTS WITH NEW-ONSET MULTIDRUG-RESISTANT MYCOBACTERIUM PULMONARY TUBERCULOSIS IN THE EARLY USE OF A RESERVE CHEMOTHERAPY REGIMEN ACCORDING TO THE TB-BIOCHIP TEST SYSTEM DATA].\",\"authors\":\"\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Clinical and X-ray changes were comparatively studied in new-onset tuberculosis patients excreting susceptible Mycobacterium tuberculosis (MBT) and mutidrug resistant (MDR) MBT. Eighty tuberculosis patients who had not received antituberculous drugs were followed up. Before chemotherapy, sputum was tested in all cases, by using the TB-biochip system, to determine drug susceptibility of MBT. According to the results of microchip diagnosis, the patients were divided into 2 groups: 1) patients with primary MRD MBT (a study group) and 2) those with MBT susceptible to all drugs (a control group). A chemotherapy regimen involving a combination of reserve drugs was given in Group 1 while Group 2 received standard regimen 1 that comprised basic series drugs. The timely use of the adequate therapy regimen in patients with MDR tuberculosis could achieve a high efficiency of therapy in a short period in terms of the bacterial excretion rate in 97.5 and 100% and in the terms of the decay cavity healing rate in 92.5 and 97.5% in Groups 1 and 2, respectively At the same time after termination of a 6-month course of therapy, both groups showed a preponderance of minimum residual changes as scars (37.5 and 45.0%) and fibrous foci (52.5 and 50.0%).</p>\",\"PeriodicalId\":37828,\"journal\":{\"name\":\"Tuberculosis and Lung Diseases\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Tuberculosis and Lung Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tuberculosis and Lung Diseases","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
[CLINICAL AND X-RAY CHANGES IN PATIENTS WITH NEW-ONSET MULTIDRUG-RESISTANT MYCOBACTERIUM PULMONARY TUBERCULOSIS IN THE EARLY USE OF A RESERVE CHEMOTHERAPY REGIMEN ACCORDING TO THE TB-BIOCHIP TEST SYSTEM DATA].
Clinical and X-ray changes were comparatively studied in new-onset tuberculosis patients excreting susceptible Mycobacterium tuberculosis (MBT) and mutidrug resistant (MDR) MBT. Eighty tuberculosis patients who had not received antituberculous drugs were followed up. Before chemotherapy, sputum was tested in all cases, by using the TB-biochip system, to determine drug susceptibility of MBT. According to the results of microchip diagnosis, the patients were divided into 2 groups: 1) patients with primary MRD MBT (a study group) and 2) those with MBT susceptible to all drugs (a control group). A chemotherapy regimen involving a combination of reserve drugs was given in Group 1 while Group 2 received standard regimen 1 that comprised basic series drugs. The timely use of the adequate therapy regimen in patients with MDR tuberculosis could achieve a high efficiency of therapy in a short period in terms of the bacterial excretion rate in 97.5 and 100% and in the terms of the decay cavity healing rate in 92.5 and 97.5% in Groups 1 and 2, respectively At the same time after termination of a 6-month course of therapy, both groups showed a preponderance of minimum residual changes as scars (37.5 and 45.0%) and fibrous foci (52.5 and 50.0%).
期刊介绍:
The Journal is aimed for professional development of researchers, doctors, teachers of medical universities and training institutions. The Journal focuses on the presentation of results of research, case studies, issues of differential diagnostics and treatment in the phthisiologist’s practice, national programs on tuberculosis control in the Russian Federation, WHO strategies, discussion of prevention issues to stop transmission of TB/HIVco-infection, and extrapulmonary tuberculosis.